Dimensional Fund Advisors LP Reduces Stake in Corcept Therapeutics Incorporated $CORT

by · The Cerbat Gem

Dimensional Fund Advisors LP reduced its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 4.1% during the first quarter, Holdings Channel.com reports. The institutional investor owned 1,553,135 shares of the biotechnology company’s stock after selling 67,198 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Corcept Therapeutics were worth $62,597,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CORT. Pathstone Holdings LLC lifted its stake in Corcept Therapeutics by 0.8% in the third quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock worth $1,497,000 after acquiring an additional 144 shares during the period. Gould Capital LLC raised its holdings in Corcept Therapeutics by 50.0% in the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 200 shares in the last quarter. Sequoia Financial Advisors LLC lifted its position in shares of Corcept Therapeutics by 3.7% in the 4th quarter. Sequoia Financial Advisors LLC now owns 6,904 shares of the biotechnology company’s stock worth $240,000 after purchasing an additional 247 shares during the period. Evergreen Capital Management LLC lifted its position in shares of Corcept Therapeutics by 3.0% in the 4th quarter. Evergreen Capital Management LLC now owns 8,609 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 248 shares during the period. Finally, Deutsche Bank AG boosted its stake in shares of Corcept Therapeutics by 3.4% during the 4th quarter. Deutsche Bank AG now owns 8,446 shares of the biotechnology company’s stock valued at $294,000 after purchasing an additional 279 shares in the last quarter. Institutional investors own 93.61% of the company’s stock.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

  • Positive Sentiment: Corcept reported second-quarter earnings of $0.36 per share, well above the $0.02 analyst consensus, while revenue reached $256.15 million versus expectations of $221.15 million. Revenue increased 31.7% year over year, helping drive the stock to a new 12-month high. Corcept Therapeutics Reaches New 12-Month High After Better-Than-Expected Earnings
  • Positive Sentiment: Piper Sandler initiated or reiterated an “Overweight” rating, adding to the bullish analyst sentiment surrounding Corcept’s growth outlook. Corcept Therapeutics Earns Overweight Rating from Piper Sandler
  • Positive Sentiment: HC Wainwright sharply raised its Q3 2026 EPS estimate to $0.78 from $0.34 and lifted its full-year 2026 forecast to $2.15 from $0.80. The firm maintained a “Buy” rating and a $165 price target, implying continued confidence in near-term earnings momentum.
  • Neutral Sentiment: Analyst coverage remains mixed: HC Wainwright’s revised estimates imply strong 2026 earnings growth, but the firm reduced several 2027 quarterly forecasts and lowered FY2027 EPS to $3.95 from $5.38. This suggests expectations for longer-term growth have moderated.
  • Negative Sentiment: Some investors may be concerned that the stock’s rapid rise has already priced in much of LIFYORLI’s potential. A recent analysis described the drug as likely to become a blockbuster but warned that Corcept’s valuation leaves limited room for disappointment. Corcept Therapeutics: LIFYORLI Is Likely a Blockbuster, But the Valuation Already Knows It

Corcept Therapeutics Stock Down 3.2%

Corcept Therapeutics stock opened at $114.49 on Friday. Corcept Therapeutics Incorporated has a twelve month low of $28.66 and a twelve month high of $122.21. The company has a market capitalization of $12.38 billion, a P/E ratio of 272.60 and a beta of 0.47. The stock’s 50 day moving average is $84.77 and its 200 day moving average is $56.78.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.02 by $0.34. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The business had revenue of $256.15 million for the quarter, compared to the consensus estimate of $221.15 million. During the same period in the previous year, the company posted $0.29 earnings per share. The company’s revenue for the quarter was up 31.7% compared to the same quarter last year. As a group, equities analysts expect that Corcept Therapeutics Incorporated will post 1.13 EPS for the current year.

Insider Transactions at Corcept Therapeutics

In related news, insider William Guyer sold 20,000 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $93.13, for a total value of $1,862,600.00. Following the transaction, the insider owned 3,985 shares in the company, valued at $371,123.05. The trade was a 83.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director James N. Wilson sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $83.20, for a total transaction of $832,000.00. Following the sale, the director owned 1,094,543 shares of the company’s stock, valued at approximately $91,065,977.60. This represents a 0.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 300,000 shares of company stock worth $22,088,050 over the last quarter. Corporate insiders own 20.70% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on CORT. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price target on the stock. in a research report on Monday, July 27th. Truist Financial upgraded Corcept Therapeutics to a “strong-buy” rating in a report on Monday, June 15th. Canaccord Genuity Group increased their target price on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Wednesday. HC Wainwright raised their target price on Corcept Therapeutics from $95.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Corcept Therapeutics in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $119.17.

Read Our Latest Research Report on CORT

Corcept Therapeutics Profile

(Free Report)

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.

Featured Stories

Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report).